Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer

Abstract excerpt

Abstract Current treatments for castration resistant prostate cancer (CRPC) largely fall into two classes: androgen receptor (AR)-targeted therapies such as the next-generation antiandrogen therapies (NGAT), enzalutamide and abiraterone, and taxanes such as docetaxel and cabazitaxel. Despite improvements in outcomes, patients still succumb to the disease due to the development of resistance. Further complicating...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Prostate Cancer Treatment and Research
• Share to Protein Degradation and Inhibitors
• Share to Radiopharmaceutical Chemistry and Applications